Document:

Exhibit 10.2

 

AMENDED AND RESTATED AGREEMENT

 

THIS AMENDED AND
RESTATED AGREEMENT (the “Agreement”) is made as of the 30 day of September, 2019 by and between Hudson Technologies,
Inc., P.O. Box 1541, One Blue Hill Plaza, Pearl River, New York 10965 (“HTI”), Hudson Technologies Company, P.O. Box
1541, One Blue Hill Plaza, Pearl River, New York 10965 (“HTC” and hereinafter HTI, HTC and their Affiliates are collectively
referred to herein as “Hudson”) and Kathleen L. Houghton, currently residing at 32 Turner Road, Pearl River, NY, 10965
(“Executive”).

 

WHEREAS, the
Executive has recently been promoted to, and now holds the title of Vice President Sales and Marketing of HTC;

 

WHEREAS, the
parties acknowledge that, because the Executive’s duties and responsibilities will bring the Executive into contact with
Hudson’s confidential information, Hudson must ensure that its valuable confidential information, as well as its customer
relationships, are protected and can be entrusted to the Executive;

 

WHEREAS, the
parties acknowledge that the Executive’s talents, knowledge and services to HTC are of a special, unique, and extraordinary
character and are of particular and peculiar benefit and importance to Hudson;

 

WHEREAS, Hudson
desires to ensure that it will receive the dedication, loyalty and service of, and the availability of objective advice and counsel,
from the Executive, as well as assurances that the Executive will devote her best efforts to her employment with Hudson and that
she will not solicit other executives or employees of Hudson;

 

WHEREAS, Hudson
and the Executive previously entered into an Agreement dated August 22, 2019 (the “Prior Agreement”);

 

WHEREAS, HTI
is the ultimate parent company of HTC and is made a party to this agreement for the sole purpose of implementing the terms of this
agreement; and

 

WHEREAS, the
parties desire to amend and restate the Prior Agreement on the terms contained herein.

 

NOW THEREFORE,
in consideration of the continued employment by HTC of the Executive, and in consideration of the rights and benefits granted and
the mutual covenants and conditions contained herein, and for other good and valuable consideration, receipt of which is hereby
acknowledged, it is agreed that the Prior Agreement is hereby amended and restated as follows:

 

1.                 
TERMINATION: The following payments and benefits (hereinafter “Severance Benefits”) will be provided to the
Executive by HTC in the event of a Termination of Employment (as hereinafter defined):

 

    1

     

    

 

A.              
Executive will continue to receive her annual base salary, based upon her annual base salary in effect as of the date of her Termination
of Employment, for a period of twelve (12) months (the “Severance Period”), in accordance with HTC’s normal
payroll practice in effect as of the date of this Agreement. HTC shall deduct from Executive’s continuing payroll all normal
tax withholdings and deductions which HTC is required by law to make. The initial payment shall be made within the forty-five (45)
day period following the Executive’s Termination of Employment and the Executive shall have no right to designate the taxable
year of payment.

 

B.              
Within the forty-five (45) day period following the Executive’s Termination of Employment, HTC will pay to the Executive
a lump sum payment in an amount equal to a pro rata bonus through the date of Termination of Employment (the “Pro-Rata Bonus”).
For purposes of this paragraph “1.B.”, the Pro-Rata Bonus shall be an amount equal to the highest bonus earned by the
Executive in any calendar year within the three (3) calendar years immediately preceding the date of Termination of Employment,
pro-rated for the period served during the year in which the Termination of Employment occurs. HTC shall deduct from this bonus
payment all normal tax withholdings and deductions which HTC is required by law to make. The Executive shall have no right to designate
the taxable year of payment.

 

Notwithstanding the
foregoing, HTC shall not be obligated to pay the Pro-Rata Bonus to the Executive if as of the date of Termination of Employment
(i) HTC is operating at a level of performance, on a year to date basis, below HTC’s net profit goals as established by HTC’s
Budget (as hereinafter defined), or (ii) the Executive is acting at a level of performance, on a year to date basis, such that
she has not achieved all of the performance criteria established by the Executive’s Budget (as hereinafter defined). For
purposes of this paragraph “1.B.”, Hudson shall prepare a profit and loss statement showing HTC’s total year
to date net profit as of the close of business the day prior to the date of Termination of Employment, and as compared to the net
profit under HTC’s Budget (the “Interim P&L”).

 

C.              
Within the forty-five (45) day period following the Executive's Termination of Employment, HTC will pay to the Executive a lump
sum payment for the Executive's unused vacation for the year in which the Termination of Employment occurs, equal to the number
of pro rata unused vacation days on the date of the Termination of Employment, as determined in accordance with HTC’s
standard vacation policy, multiplied by the Executive's daily base salary on the date of Termination of Employment. HTC shall deduct
from this payment all normal tax withholdings and deductions which HTC is required by law to make. The Executive shall have no
right to designate the taxable year of payment.

 

D.              
The Executive’s participation in life, health and dental insurance, disability insurance, and any other benefits (the “Benefits”)
provided by HTC to the Executive as of the date of the Termination of Employment shall be continued, or essentially equivalent
benefits provided by HTC, for the entire Severance Period or until otherwise terminated by the Executive, on the same terms, conditions
and costs as if the Executive continued in the employ of HTC. To the extent Benefits include health and dental insurance, such
Benefits shall be provided as COBRA continuation coverage, and not in addition to COBRA. Notwithstanding the foregoing, to the
extent Benefit coverages provided to the Executive under this paragraph are taxable to the Executive, Hudson’s obligation
hereunder shall not exceed the applicable dollar amount under Section 402(g)(1)(B) of the Internal Revenue Code of 1986, as amended
(the “Code”) determined as of the year in which the Executive’s “Separation of Service” occurs, which
is exempt under Treas. Reg. Section1.409A-1(b)(9)(v)(D)(Limited Payment).

 

    2

     

    

 

E.                
All stock options, stock appreciation rights, and any similar rights which the Executive holds on the date of Termination of Employment
shall become fully vested and be exercisable on the date of Termination of Employment, and shall remain exercisable following the
Termination of Employment until (i) expiration of the Severance Period, (ii) termination of Severance Benefits pursuant to paragraph
 “6” below, or (iii) expiration of the original term of the stock option, stock appreciation right or similar right,
whichever first occurs. No extension of an exercise period under this Agreement shall extend to a date that would cause a stock
option, stock appreciation right or similar right to be subject to Code Section 409A.

 

 F.                
 For the purposes of this Agreement, the following definitions will apply:

 

(i)           
A “Termination of Employment” shall take place in the event that the Executive’s employment is terminated (a)
by HTC without Cause (as hereinafter defined) or (b) by the Executive following an event constituting Good Reason (as hereinafter
defined).

 

(ii)       
 “Cause” shall exist if the act(s) or conduct of the Executive make it unreasonable to require HTC to continue to retain
Executive in its employment, such as, but not limited to, (a) the Executive’s willful and continued refusal to perform, or
the Executive’s willful and continued neglect of, the substantive duties of her position, (b) any willful act or omission
by the Executive constituting dishonesty, fraud or other malfeasance, (c) material nonconformance with Hudson’s standard
business practices and policies, including but not limited to violation of Hudson’s Code of Business Conduct and Ethics or
Hudson’s Substance Abuse Policy, (d) any act or omission by the Executive which has a material adverse effect upon the financial
condition or business reputation of Hudson, (e) the Executive’s conviction of a felony, or any crime involving moral turpitude,
dishonesty or theft, under the laws of the United States, or any state thereof or any other jurisdiction in which Hudson conducts
business, (f) breach of the provisions of paragraphs “4” or “5” of this Agreement, or (g) the resignation
of Executive other than pursuant to the occurrence of an event constituting Good Reason (as hereinafter defined).

 

(iii)     
 “Good Reason shall mean the occurrence of any of the following: (a) the Executive is assigned any duties or responsibilities,
without her consent, that are materially inconsistent with her position, duties, responsibilities, or status; (b) except as provided
in paragraph “1.I.” below, the Executive’s annual base salary is reduced, except to the extent that the annual
base salaries of all Executive Officers (as defined below) are reduced due to the adverse financial condition of Hudson and further
providing that the Executive’s annual base salary may not be reduced to a level that is less than ninety percent (90%) of
the Executive’s annual base salary as of the date herein; (c) the Executive’s benefits are reduced and such reduction
results in a material reduction in the Executive’s total compensation, except to the extent that such reductions are made
by Hudson on a company-wide basis and affect all the Executive Officers that participate in such benefits; or (d) except as provided
in paragraph “1.I.” below, the Executive experiences in any year a reduction in bonus compensation, or other incentive
compensation, bonus or other such payments to her base compensation, or a reduction in the method of calculation of the Executive’s
incentive compensation, bonus or other such payments if these benefits or payments are calculated other than as a percentage of
base salary, except to the extent such reduction applies equally or proportionally, as the case may be, to all Executive Officers
of Hudson. Good Reason shall not be deemed to exist unless the Executive’s Termination of Employment for Good Reason occurs
within ninety (90) days following the initial existence of one of the foregoing conditions, the Executive provides Hudson with
written notice of the existence of such condition(s) within thirty (30) days after the initial existence of the condition(s), and
Hudson fails to remedy the condition within thirty (30) days after its receipt of such notice. An isolated, insubstantial and inadvertent
action not taken in bad faith and which is remedied by Hudson within ten (10) days after Hudson’s receipt of notice thereof
given by the Executive shall not constitute Good Reason.

 

    3

     

    

 

(iv)      
 “Budget” shall mean (a) as to HTC, the projected annual and monthly revenues, expenses and net profit goals approved
and accepted by HTC’s board of directors for the applicable fiscal year, and for each month individually in that fiscal year,
and (b) as to Executive, all performance criteria capable of being measured on a month to month basis, if any, that have been established
for the Executive under any bonus or other incentive compensation plan covering the applicable fiscal year.

 

(v)        
 “Executive Officer(s) shall mean the following: Hudson’s Chief Executive Officer (currently Kevin J. Zugibe); Hudson’s
President and/or Chief Operating Officer (currently Brian Coleman); Hudson’s Chief Financial Officer (currently Nat Krishnamurti);
HTC’s Vice President Sales and Marketing (currently Executive); Robert Stoody, Vice President Military & Gases Sales
Division, and any other current or future officer of Hudson.

 

(vi)      
 “Affiliate” means, with respect to Hudson, any other Person that is directly or indirectly Controlling, Controlled
by, or under common Control with HTI, where “Control” and derivative terms mean the possession, directly or indirectly,
of the power to direct or cause the direction of the management and policies of a Person, whether through the ownership or voting
securities, by contract, or otherwise, and includes, without limitation, HTI, HTC, Hudson Holdings, Inc. and Aspen Refrigerants,
Inc.

 

G.               
HTC’s obligation to pay the compensation and to make the arrangements provided in this paragraph “1” shall be
absolute and unconditional and shall not be affected by any circumstances, including, without limitation, any offset, counterclaim,
recoupment or other right which Hudson may have against the Executive or anyone else; provided, however that as a condition to
payment of amounts under this paragraph “1”, within sixty (60) days of the Executive’s Termination of Employment,
the Executive shall have (i) executed and not revoked a general release and waiver, in form and substance reasonably satisfactory
to Hudson and the Executive, of all claims relating to the Executive’s employment by HTC and the termination of such employment,
including, without limitation, discrimination claims (including without limitation age discrimination), employment-related tort
claims, contract claims and claims under this Agreement (other than claims with respect to benefits under any tax -qualified retirement
plans or continuation of coverage or benefits solely as required under ERISA) with such general release and waiver having become
irrevocable, and (ii) executed an agreement expressly acknowledging and reaffirming the covenants and restrictions contained in
paragraphs “4” and “5” below, and the remedies available to Hudson under paragraph “6” below.

 

    4

     

    

 

H.               
All amounts payable by HTC pursuant to this paragraph “1” shall be paid without notice or demand. The Executive shall
not be obligated to seek other employment in mitigation of the amounts payable or arrangements made pursuant to this paragraph
 “1” and, except as provided in paragraph “6” below, the obtaining of any other employment shall not result
in a reduction of HTC’s obligation to make the payments, benefits and arrangements required to be made under this paragraph
 “1”.

 

I.                   
Executive expressly acknowledges that the following shall not constitute “Good Reason” for purposes of this paragraph
 “1”:

 

(i)         
Establishing a new or different bonus or incentive compensation plan(s) in any subsequent year based upon new or different criteria
for calculating the applicability of, and the amount of any bonus or incentive compensation award due to the Executive, provided
that any new or different bonus or incentive compensation plan, and any award under said plan, applies equally or proportionally,
as the case may be, to all Executive Officers; except that Hudson may establish separate performance criteria and payment amounts
for awards under such plan for each Executive Officer that are reasonably achievable and reasonably related to such Executive Officer’s
normal duties and responsibilities;

 

(ii)         A reduction of the Executive’s bonus compensation or other incentive compensation that (a) results from HTC operating at
a level of performance below HTC’s Budget, (b) results from the Executive’s failure or inability to attain, in whole
or in part, any or all of the performance criteria established for the Executive under the said plan, (c) results from the application
of the terms of such bonus or incentive compensation plan, or (d) is based upon the Executive’s performance or non-performance,
of her normal duties and responsibilities during the period covered by the bonus or incentive compensation plan including, without
limitation, due to the Executive’s Disability (as defined herein);

 

(iii)       A reduction of the Executive’s annual base salary based upon the Executive’s performance or non-performance, of her
normal duties and responsibilities, provided that the Executive’s annual base salary may not be reduced to a level that is
less than ninety (90%) percent of the Executive’s annual base salary for the calendar year immediately prior to the Termination
of Employment; or

 

(iv)       A reduction in the Executive’s annual base salary pursuant to the provisions of paragraph “3” below.

 

2.                 
TERMINATION FOR CAUSE: HTC may at any time terminate the employment of the Executive for Cause (as defined in paragraph
 “1F” above) upon five (5) days prior written notice to Executive. If Executive is terminated for Cause, she shall be
entitled to no Severance Benefits and shall be entitled to no bonus payment that might otherwise be owed to her if she worked for
the entire year. In the event of termination under this paragraph, HTC shall pay Executive all amounts which are then accrued but
unpaid, including unpaid vacation as determined in accordance with Hudson’s’ standard vacation policy, within thirty
(30) days after the date of notice. Hudson shall have no further or additional liability to Executive.

 

    5

     

    

 

 3.                 
 SICK LEAVE:

 

A.               
If with or without reasonable accommodation Executive is physically or mentally unable to perform her duties, or is otherwise absent
for medical reasons, HTC shall continue to pay base salary and provide benefits to the Executive (“Sick Leave”). However,
if a continuous period of Sick Leave exceeds eight (8) consecutive weeks, HTC’s obligation with regard to base salary upon
the expiration of the eight (8) consecutive weeks shall be limited to paying 75% of base salary. If the Executive returns to full
service, her full base salary shall be reinstated to the pre-adjustment amount. As a condition to the receipt of the foregoing
base salary and benefits, the Executive agrees that she shall provide Hudson such information as Hudson may reasonably request
from time to time to permit Hudson to make a determination that the Executive is entitled to sick pay under this provision. HTC
shall reduce the amount paid to the Executive during such Sick Leave by an amount equal to any disability payments or benefits
actually received by Executive under or pursuant to any disability program or supplemental disability insurance plan(s) provided
by Hudson at Hudson’s expense unless such reduction results in a violation of Code Section 409A.

 

B.                
Notwithstanding the foregoing, HTC may terminate the employment of Executive at any time after Executive’s continuous period
of Sick Leave exceeds 120 calendar days. Termination of the Executive after the said 120 calendar period shall not be deemed a
Termination for Cause (as defined in paragraph “1.F” above) and shall entitle the Executive to receive the payments
and benefits provided by paragraph “1” upon Termination of Employment based upon Executive’s full base salary,
and for purposes of such payments and benefits, the Severance Period shall be deemed to commence as of the date of the Termination
of Employment resulting under this paragraph “3.B.”.

 

C.                
Notwithstanding anything to the contrary contained herein, in the event that during the period the Executive is on Sick Leave,
and prior to any Termination of Employment pursuant to paragraph “3.B.”, there is deemed a “Separation from Service”
(as that term is defined in Code Section 409A for purposes of a permissible payment event), Hudson and the Executive agree that
such Separation of Service shall be treated as a Termination of Employment. Such termination shall not be deemed a Termination
for Cause (as defined in paragraph “1.F.” above) and shall entitle the Executive to receive the payments and benefits
provided by paragraph “1” upon Termination of Employment based upon Executive’s full base salary, provided that,
for purposes of such payments and benefits, the Severance Period shall commence as of the date of the Separation from Service as
described in this paragraph “3.C.”, and shall be based upon Executive’s full base salary.

 

D.               
Notwithstanding anything to the contrary contained herein, in the event that during the period the Executive is on Sick Leave,
and prior to any Termination of Employment pursuant to paragraph “3.B.” or any Separation from Service pursuant to
paragraph “3.C.” , the Executive becomes “Disabled”, (as defined in Code Section 409A for purposes of a
permissible payment event) Hudson and the Executive agree that the Executive’s Disability shall entitle the Executive to
receive the payments and benefits provided by paragraph “1” upon Termination of Employment based upon Executive’s
full base salary. For purposes of such payments and benefits, the Severance Period shall commence as of the date of the Disability
as described in this paragraph “3.D.”.

 

    6

     

    

 

 4.                 
 CONFIDENTIALITY:

 

A.                
Executive expressly acknowledges and agrees as follows:

 

(i)       
Hudson expends a significant amount of funds annually on researching and developing solutions and proprietary techniques related
to the products and services it offers or is seeking to offer, and has developed substantial confidential, proprietary, and trade
secret information, and this confidential, proprietary and trade secret information, if misused, disclosed, misappropriated or
used by others, would result in irreparable harm to Hudson and/or its Affiliates.

 

(ii)       
Hudson’s Confidential Information (as hereinafter defined) constitutes valuable commercial assets of Hudson and is not readily
available to the general public or any persons not employed by or otherwise not associated in a position of trust with Hudson.
Hudson keeps its Confidential Information confidential (other than to the extent filings are required for patents) by, among other
things, restricting access to only those who need the information to perform their Hudson job function and prohibiting the use
or disclosure of Confidential Information to anyone not authorized to receive or use the Confidential Information.

 

(iii)       
Executive’s position with HTC will continue to provide Executive with access to or knowledge of Hudson’s Confidential
Information.

 

(iv)      
Hudson’s Confidential Information will become known to Executive only as a result of his/her employment with HTC. To the
extent that Executive was previously engaged, on her own or with others, in a business that provided the same or similar services
as those provided by Hudson, Executive further acknowledges that such prior business knowledge and experience, and any familiarity
with entities that are actual or potential customers for the business, shall not permit or allow Executive to contend that Hudson’s
Confidential Information is not confidential or should not be protected from use or misappropriation.

 

B.                
In light of the foregoing, Executive acknowledges and agrees as follows:

 

(i)          All Confidential Information is the property of Hudson, and Executive shall not, without the express written consent of Hudson,
directly or indirectly use, disseminate, disclose, or in any way reveal, either during Executive’s employment or at any time
thereafter, all or any part of the Confidential Information, other than for the purposes authorized by Hudson, or only for the
benefit of Hudson.

 

(ii)       
Hudson shall be the sole owner of, and Executive hereby assigns to Hudson, any and all property rights to all Intellectual Property
(as hereinafter defined) made, conceived, originated, devised, discovered, invented, or developed before, during or after the term
of Executive’s employment with HTC, whether or not Executive was involved either alone or with others, if it was in whole
or in part developed during the course of Executive’s employment or by Executive’s use of any property of Hudson. This
ownership provision does not apply to creations of the Executive which are made in the Executive’s own time, without the
use of any Hudson resources, and which do not relate in any way to Hudson’s business. Executive agrees to cooperate fully
and assist Hudson or its designee in the performance of any lawful acts that Hudson at its discretion deems necessary, and to execute
and deliver without charge any documents reasonably required by Hudson, to secure any patent, copyright, trademark, and other protection
for Intellectual Property and improvements thereon, and to assign to and vest in Hudson the entire interest therein in the United
States and all foreign countries.

 

    7

     

    

 

(iii)     
Upon request by Hudson at any time, or upon termination of employment with HTC, whichever is sooner, Executive shall immediately
deliver to Hudson any and all information and property of Hudson in whatever form it exists, including but not limited to all Confidential
Information and all copies thereof or materials containing or derived from Confidential Information.

 

C.                
As used in this Agreement, “Confidential Information” means all information of Hudson and its Affiliates that is not
publicly available (but including information that is publicly available as a result of a breach by Executive of paragraphs “4”
and “5”) and not generally known or used by Hudson’s competitors, or in the industry, and which could be harmful
to Hudson and/or its Affiliates if disclosed to persons outside of Hudson and which includes, but is not limited to:

 

(i)         
Intellectual Property (as hereinafter defined);

 

(ii)         Technical information, such as, but not limited to: Hudson’s plant organization and designs; product formulation, manufacturing,
performance and processing data; and research and development results and plans;

 

(iii)       
Product information, such as, but not limited to: non-public details of Hudson’s and its Affiliates’ products and services,
including but not limited to, its existing refrigerant, decontamination, reclamation and recovery products and services, as well
as those being developed; specialized equipment and training; product plans, drawings and specifications; and performance capabilities,
strengths and weaknesses;

 

(iv)       Strategic information, such as, but not limited to: Hudson’s and its Affiliates’ material costs; supplier and vendor
information; overhead costs; pricing; profit margins; banking and financing information; and market penetration initiatives and
strategies;

 

(v)        Organizational information such as, but not limited to: Hudson’s and its Affiliates’ personnel and salary data; information
concerning the utilization of facilities; merger, acquisition and expansion information; equipment utilization information; and
Hudson and its Affiliates’ manuals, policies and procedures;

 

    8

     

    

 

(vi)      
Marketing and sales information, such as, but not limited to: Hudson’s and its Affiliates’ licensing, marketing and
sales techniques and data; customer lists; customer data, such as, but not limited to, their personnel, project, financial and
account status, individual needs, historical purchases, and contact information; product development and delivery schedules; market
research and forecasts; and marketing and advertising plans, techniques and budgets; and

 

(vii)   
Advertising information, such as, but not limited to: Hudson’s and its Affiliates’ overall marketing policies; the
specific advertising programs and strategies utilized by Hudson; and the success or lack of success of those programs and strategies.

 

“Confidential
Information” does not include general skills, experience or information that is generally available to the public, other
than information which has become generally available as a result of Executive’s direct or indirect act or omission. “Confidential
Information” also does not include information regarding Executive’s own pay and benefits, information as to the terms
and conditions of employment, or information that is deemed not confidential under Section 7 of the National Labor Relations Act.
Executive understands that nothing contained in this Agreement limits Executive’s ability to file a charge or complaint with
the Equal Employment Opportunity Commission, the National Labor Relations Board, the Occupation Safety and Health Administration,
the Securities and Exchange Commission, or any other federal, state or local governmental agency or commission (“Government
Agencies”). Executive further understands that this Agreement does not limit Executive’s ability to communicate with
any Government Agency, including providing documents or other information, without notice to Hudson. This Agreement does not limit
Executive’s right to receive an award for information provided to any Government Agencies.

 

D.               
As used in this Agreement, “Intellectual Property” means all information concerning the evaluation, design, engineering,
construction, marketing, and sales of the products and services provided by Hudson and which includes, but is not limited to: any
and all patents, patents pending; trademarks, copyrights, and any and all applications for same issued to and/or applied for by
Hudson; any and all technological (including software), educational, operational, and financial innovations, discoveries, inventions,
designs, and formulae; tests; performance data; process or production methods; improvements to all such property; and all recorded
material defining, describing, illustrating, or documenting in any fashion, all such property, whether written or not and regardless
of the medium in which the information is stored or recorded; without regard to whether such property is patentable, copyrightable,
or subject to trade/service mark protection, and without regard to whether a patent, copyright, or trademark or service mark has
been sought or obtained.

 

E.                
Notwithstanding anything in this Agreement, Executive is hereby advised that pursuant to the federal Defend Trade Secrets Act:
(i) an individual shall not be held criminally or civilly liable under any federal or state trade secret law for the disclosure
of a trade secret that (a) is made (1) in confidence to a federal, state, or local government official, either directly or indirectly,
or to an attorney; and (2) solely for the purpose of reporting or investigating a suspected violation of law; or (b) is made in
a complaint or other document filed in a lawsuit or other proceeding, if such filing is made under seal; and (ii) an individual
who files a lawsuit for retaliation by an employer for reporting a suspected violation of law may disclose the trade secret to
the attorney of the individual and use the trade secret information in the court proceeding, if the individual (a) files any document
containing the trade secret under seal; and (b) does not disclose the trade secret, except pursuant to court order.

 

    9

     

    

 

 5.                  NON-COMPETITION / NON-SOLICITATION:

 

A.               
Executive expressly acknowledges and agrees as follows:

 

(i)         Hudson compensates its employees, among other things, to develop and to pursue, on Hudson’s behalf, good relationships and
goodwill with all customers and potential customers, whether developed by Executive or others within the Hudson organization;

 

(ii)       
Executive will be exposed to, acquire and develop knowledge of Confidential Information including, without limitation, Confidential
Information related to Hudson’s customers, operations, and its suppliers;

 

(iii)      
Executive is able to be gainfully employed by other employers in a variety of other industries and businesses that are engaged
in businesses that do not involve and are not competitive with any part of Hudson’s business.

 

B.                
In light of the foregoing, Executive agrees, that while Executive is employed by HTC, and continuing until the expiration of the
Covenant Period (as hereinafter defined):

 

(i)          
Executive shall not, within the Restricted Territory (as hereinafter defined), compete with Hudson or its Affiliates, directly
or indirectly, whether for Executive’s own behalf or on behalf of or in conjunction with any other person, persons, company,
partnership, corporation or business entity, whether for profit or not-for-profit, by being employed by, participating in, or otherwise
being materially connected in the conduct of any business activity that involves providing products or services that are like or
similar to, or competitive with, or would replace or be a substitute for, any one or more of the products and services provided
by Hudson and/or by its Affiliates (hereinafter Competitive Products”) if such employment, participation, or connection involves
(a) responsibilities similar to responsibilities Executive had or performed for Hudson at any time during the last eighteen (18)
months of Executive’s employment with HTC; (b) supervision of employees or other personnel in the provision of Competitive
Products; (c) development or implementation of strategies or methodologies related to the provision of Competitive Products; (d)
marketing or sale of Competitive Products; or (e) responsibilities in which Executive would utilize or disclose Confidential Information.

 

(ii)       
Executive shall not compete with Hudson or with any Affiliate, directly or indirectly, whether for Executive’s own behalf
or on behalf of or in conjunction with any other person, persons, company, partnership, corporation or business entity, whether
for profit or not-for-profit, by calling upon, contacting, diverting, soliciting, or doing business for or with any “Client”
of Hudson or any Affiliate (as hereinafter defined) for the purpose of offering or providing any Competitive Products.

 

    10

     

    

 

(iii)     
Executive shall not directly or indirectly, without the prior written consent of Hudson, (a) induce, solicit, entice, or encourage
any officer, director, employee or other individual to leave his or her employment with Hudson or any Affiliate, (b) induce, solicit,
entice, or encourage any officer, director, employee or other individual to compete in any way with the products and services of
Hudson or any Affiliate, or to violate the terms of any employment, non-competition, confidentiality or similar agreement with
Hudson or any Affiliate; or (c) employ, offer to employ, contract with, offer to contract with, or do business with any officer,
director, employee or other individual who is employed by Hudson or any Affiliate.

 

C.               
For purposes of this paragraph “5”, the Covenant Period shall be twelve (12) months after the Executive’s last
day of active employment with HTC, regardless of the reason underlying the termination of Executive’s employment.

 

D.               
Executive acknowledges that many of Hudson’s services are remedial in nature and, as such, its customers may utilize Hudson’s
services on an infrequent basis over an extended period of time or following a protracted sales effort over an extended period
of time. Executive also acknowledges that because of her position, she will likely have knowledge of Hudson’s customers through
access to Confidential Information, whether or not located within the Restricted Territory (hereinafter defined). Accordingly,
for purposes of this paragraph “5”, the term “Client” shall mean (a) any customer or potential customer
of Hudson upon whom Executive, during the last eighteen (18) months of Executive’s employment with Hudson, called upon or
with whom Executive had any contact, or as to whom Executive was involved in regard to planning, marketing, conducting, or overseeing
an offer to sell products or perform services; (b) any customer as to whom Executive assisted in selling products or providing
services, or as to whom Executive was involved in regard to planning, marketing, conducting, or overseeing the offer to sell products
or perform services if the customer received any products or services from Hudson during the last eighteen (18) months of Executive’s
employment with Hudson; (c) any potential customer of Hudson whose identity Executive learned during the eighteen (18) months of
Executive’s employment with Hudson or learned from Confidential Information at any time; or (d) any customer for whom Hudson
has provided products or services to at any time during the thirty-six (36) months preceding the last day of the Executive’s
employment with Hudson and whose identity as a Hudson customer Executive learned from Confidential Information at any time.

 

E.                
Executive acknowledges that the nature of Hudson’s business is such that provides its products and services to customers
throughout the United States of America and Puerto Rico. Accordingly, the “Restricted Territory” includes each and
every state of the United States of America (including the District of Columbia) and Puerto Rico.

 

F.                 
In order to assure Hudson of the full twelve (12) months of the Covenant Period within which to protect its goodwill and to prevent
Executive from unfairly benefiting by violations of this paragraph “5”, the provisions and requirements of this paragraph
 “5” shall be extended for a period of time beyond the Covenant Period equal in length to the total length of time during
which Executive is in violation of any one or more provisions of this paragraph.

 

    11

     

    

 

G.               
In the event it is determined by a court of competent jurisdiction that any provision or portion of a provision of this paragraph
 “5” is not enforceable under the law governing this Agreement, the unenforceable provision or portion thereof may be
stricken, and the remainder of the provision and of this paragraph “5” shall be valid and fully enforceable, in all
respects, as if the provision or portion of a provision deemed unenforceable had never been part of the Agreement. Further, if
any provision of this Agreement is found to be overbroad or unenforceable, the court or any other authority with competent jurisdiction
is expressly authorized to conform the provision to the extent necessary to remedy any deficiency and render it valid and enforceable.

 

 6.              
 REMEDIES:

 

A.            
In the event that the Executive breaches any term or provision of paragraphs “4” or “5” of this Agreement,
Hudson shall be immediately, permanently and irreparably damaged and shall be entitled, in addition to and without limiting Hudson’s
rights to, any and all other legal and equitable remedies and damages, (i) to a temporary restraining order ex parte, to a preliminary
injunction, and to a permanent injunction, to restrain Executive’s actions or the actions of others acting in conjunction
with Executive or on Executive’s behalf, (ii) to terminate all future Severance Benefits through the remainder of the Severance
Period, and (iii) to recover from the Executive all Severance Benefits actually paid to the Executive, including any costs or expenses
actually incurred by Hudson in providing such Severance Benefits. Executive agrees that Executive will not be damaged by enforcement
of this covenant as Executive can obtain many other types of gainful employment without violating the provisions of paragraphs
 “4” or “5”, so that no bond shall be required, and if the court requires a bond to be posted, it shall
not exceed $500.00.

 

B.                
All of Executive’s covenants and obligations under paragraphs “4” and “5” of this Agreement shall
survive, and shall remain enforceable, for so long as Executive is employed and after termination of employment for any reason,
and shall survive despite future promotions, raises, changes in position or compensation, demotions and the execution of new agreements
with Hudson, and shall inure to the benefit of Hudson’s successors and assigns, unless Hudson executes in writing an agreement
expressly terminating the covenants of paragraphs “4” and “5” of this Agreement.

 

C.                
Hudson and Executive shall each bear and be responsible for their own attorneys’ fees, expenses and disbursements incurred
in any litigation brought by either party to enforce or interpret any provision contained in paragraphs “4” or “5”
of this Agreement.

 

7.                  NOTICES:
  All notices required or permitted to be given under this Agreement shall be sufficient if in writing and if sent by certified
mail, return receipt requested, to the Executive at her residence, and to Hudson at its principal office located at P.O. Box 1541,
One Blue Hill Plaza, Pearl River, New York 10965, attention Chief Executive Officer, or at such other address as any party specifies
by giving proper notice.

 

8.                 
SUCCESSORS: This Agreement shall be binding upon and shall inure to the benefit of the Executive and her estate. Neither
this Agreement nor any rights hereunder shall be assignable by the Executive.

 

    12

     

    

 

This Agreement shall
be freely assignable by Hudson to, and shall inure to the benefit of, and be binding upon, any successor corporation or affiliate
of a successor corporation, and all references in this Agreement to Hudson shall include its subsidiaries and affiliates and any
successors, affiliates of successors or assigns of Hudson. As used herein, the term “successor” shall mean any person,
firm, corporation or business entity or affiliate thereof which at any time, whether by merger, purchase, or otherwise, directly
or indirectly acquires all or substantially all of the assets or the business of Hudson, including any entity that shall be the
surviving corporation in a merger with Hudson.

 

9.                EMPLOYMENT
AT WILL; CONSEQUENCES OF TERMINATION: Nothing herein shall be deemed to create an agreement for employment of Executive for
any specified term or period of time. Hudson expressly agrees that at any time the Executive may resign or otherwise terminate
his or her employment with HTC, for any reason or for no reason, subject to the provisions contained herein. Likewise, the Executive
expressly agrees that at any time HTC may terminate the employment of the Executive for any reason or for no reason, subject to
the provisions contained herein.

 

10.             
INDEMNIFICATION: In the event that any litigation shall be brought to enforce or interpret any provision contained in
paragraphs “1”, “2”, or “3” of this Agreement, then, provided that the Executive prevails to
any extent, Hudson or any successor corporation shall reimburse or indemnify the Executive for the Executive’s reasonable
attorneys’ fees, expenses and disbursements incurred in such litigation, including the costs of enforcement.

 

11.             CONTROLLING
LAW: This Agreement and all other issues regarding the employment of the Executive shall be governed by the laws of the State
of New York, without reference to its conflicts of law principles.

 

12.             
ENTIRE AGREEMENT: This Agreement represents the entire agreement and understanding of the parties regarding the employment
of the Executive, and all prior or contemporaneous agreements, representations, or understandings are expressly superseded by,
and do not survive this Agreement. Executive has not relied upon any inducement, promise, representation, or assurance, other than
those expressly set out herein. Except as expressly permitted herein, this Agreement may not be modified or amended except in writing
signed by all parties hereto.

 

 13.             
 COMPLIANCE WITH CODE SECTION 409A:

 

A.       It
is the intention of Hudson and the Executive that the payments, benefits and rights to which the Executive could be entitled pursuant
to this Agreement comply with Code Section 409A, the Treasury regulations and other guidance promulgated or issued thereunder (collectively
for purposes of this paragraph 13, “Section 409A”), to the extent that the requirements of Section 409A are applicable
thereto, and after application of all available exemptions, including but not limited to, the “short-term deferral rule”
and “involuntary separation pay plan exception” and the provisions of this Agreement shall be construed in a manner
consistent with that intention. If any provision of this Agreement (or of any award of compensation, including equity compensation
or benefits) would cause the Executive to incur any additional tax or interest under Section 409A, Hudson shall, upon the specific
request of the Executive, use its reasonable business efforts to in good faith reform such provision to comply with Section 409A;
provided, that to the maximum extent practicable, the original intent and economic benefit to the Executive and Hudson of the applicable
provision shall be maintained, but Hudson shall have no obligation to make any changes that could create any additional economic
cost or loss of benefit to Hudson. Hudson shall not have any liability to the Executive with respect to tax obligations that result
from the application of Section 409A and makes no representation with respect to the tax treatment of the payments and/or benefits
provided under this Agreement. Any provision required for compliance with Section 409A that is omitted from this Agreement shall
be incorporated herein by reference and shall apply retroactively, if necessary, and be deemed a part of this Agreement to the
same extent as though expressly set forth herein.

 

    13

     

    

 

B.       With
regard to any provision herein that provides for reimbursement of costs and expenses or in-kind benefits, except as permitted by
Section 409A, (i) the right to reimbursement or in-kind benefits is not subject to liquidation or exchange for another benefit,
(ii) the amount of expenses eligible for reimbursement, or in-kind benefits, provided during any taxable year shall not affect
the expense eligible for reimbursement, or in-kind benefits to be provided, in any other taxable year, provided that the foregoing
clause (ii) shall not be violated with regard to expenses reimbursed under any arrangement covered by Code Section 105(b) solely
because such expenses are subject to a limit related to the period the arrangement is in effect and (iii) such payments shall be
made on or before the last day of the Executive's taxable year following the taxable year in which the expense was incurred.

 

C.       For purposes of applying the provisions of Section 409A to this Agreement, each separately identified amount to which the Executive
is entitled under this Agreement shall be treated as a separate payment within the meaning of Section 409A. In addition, to the
extent permissible under Section 409A, any series of installment payments under this Agreement shall be treated as a right to a
series of separate payments.

 

D.       Neither Hudson nor the Executive, individually or in combination, may accelerate any payment or benefit that is subject to Section
409A, except in compliance with Section 409A and the provisions of this Agreement, and no amount that is subject to Section 409A
shall be paid prior to the earliest date on which it may be paid without violating Section 409A. If the consideration period (or
revocation period, if applicable) for any general release and waiver extends across two (2) calendar years, the payments to the
Executive shall begin in the second of the calendar years.

 

E.        If and to the extent required to comply with Section 409A, a Termination of Employment, as defined above, shall not be deemed to
have occurred for purposes of this Agreement providing for the payment of any amounts or benefits upon or following a Termination
of Employment unless such termination is also a “Separation from Service” within the meaning of Section 409A and, for
purposes of any provision of this Agreement, references to Termination of Employment, “termination,” “termination
of employment” or like terms shall mean “Separation from Service.”

 

    14

     

    

 

F.       If the Executive is deemed on the date of termination of his employment to be a “specified employee,” within the meaning
of that term under Section 409A(a)(2)(B) and using the identification methodology selected by Hudson from time to time, or if none,
the default methodology under Section 409A, then with regard to any payment or the providing of any benefit subject to this Agreement
and to the extent required to be delayed in compliance with Section 409A(a)(2)(B), and any other payment or the provision of any
other benefit that is required to be delayed in compliance with Section 409A(a)(2)(B), such payment or benefit shall not be made
or provided prior to the earlier of (i) the expiration of the six-month period measured from the date of the Executive’s
Separation from Service or (ii) the date of the Executive’s death. In this regard, it is the intention and understanding
of Hudson and the Executive that payments made following a Termination of Employment under paragraph “1” shall be exempt
under the “short-term deferral rule” and “involuntary separation pay plan exception”, and other applicable
exceptions, from the requirements of Section 409A(a)(2)(B) and are not required and shall not be delayed. Absent such exception,
on the first day of the seventh month following the date of Executive’s Separation from Service or, if earlier, on the date
of her death, all payments delayed pursuant to this paragraph “13.F.” (whether they would have otherwise been payable
in a single sum or in installments in the absence of such delay) shall be paid or reimbursed to the Executive in a lump sum, and
any remaining payments and benefits due under this Agreement shall be paid or provided in accordance with the normal payment dates
specified for them herein. The determination of whether the Executive is a “specified employee” shall be made by Hudson
in good faith applying Section 409A.

 

Signatures on following page

 

    15

     

    

 

 

IN WITNESS THEREOF,
the parties have executed this agreement as of the date written above.

 

	Hudson Technologies, Inc. 	 	Hudson Technologies Company
	 	 	 
	By: 	/s/ Brian F. Coleman	 	By: 	/s/ Brian F. Coleman
	Brian F. Coleman, President, COO 	 	Brian F. Coleman, President COO
	 	 	 
	/s/ Kathleen Houghton	 	 
	Kathleen HoughtonEX-10.1

 Exhibit 10.1 

EXECUTION VERSION 

ESCROW AGREEMENT 
 THIS
ESCROW AGREEMENT (this “Escrow Agreement”) is entered into and effective as of this 15th day of September, 2020, by and among PNC Bank, National Association, a national banking association (the “Escrow Agent”),
resTORbio, Inc., a Delaware corporation (“resTORbio”) and the investors listed on Schedule 1 hereto under the heading “Investors” (each of which is herein referred to as an
“Investor” and collectively as the “Investors”). Capitalized terms used but not defined herein shall have the meanings assigned to them in the Funding Agreement (as defined below). 

WHEREAS, resTORbio, Adicet Bio, Inc., a Delaware corporation (“Adicet”), and the Investors have entered into that certain
Funding Agreement dated April 28, 2020, as amended, modified or restated from time to time (the “Funding Agreement”), in connection with a merger of Oasis Merger Sub, Inc., a Delaware corporation and wholly owned subsidiary of
resTORbio (“Merger Sub”), with and into Adicet, with Adicet continuing as the surviving entity (the “Merger”), pursuant to an Agreement and Plan of Merger, dated April 28, 2020, by and among resTORbio, Adicet
and Merger Sub, as amended, modified or restated from time to time. 
 WHEREAS, pursuant to the Funding Agreement, the Investors have agreed
to deposit certain funds into an escrow account (the “Escrow Account”) immediately prior to the closing of the Merger (the “Merger Closing”) by wire transfer of immediately available cash funds, with such funds to
be held, invested and disbursed by the Escrow Agent in accordance with the terms and conditions of this Escrow Agreement and the Funding Agreement. 

WHEREAS, resTORbio, Adicet, and certain stockholders of Adicet (the “Non-Escrow
Investors”) have entered into that certain Non-Escrow Funding Agreement, dated September 15, 2020, as amended, modified or restated from time to time (the
“Non-Escrow Funding Agreement”), pursuant to which such Non-Escrow Investors have agreed to fund to resTORbio at the Concurrent Private Placement
Closing (as defined in the Funding Agreement) the amount opposite such stockholders name on Schedule A thereto. 
 WHEREAS, the
parties desire to set forth their understandings with regard to the Escrow Account established by this Escrow Agreement. 
 NOW, THEREFORE,
in consideration of the premises herein, the parties hereto agree as follows: 
 I. Terms and Conditions 

1.1.    Appointment of and Acceptance by Escrow Agent. resTORbio and each of the Investors hereby appoint the Escrow
Agent to serve as escrow agent for the purposes set forth herein, and the Escrow Agent hereby accepts such appointment and agrees to perform its duties as provided herein. 

1.2.    Establishment of Escrow. At or immediately prior to the Merger Closing, each Investor will deposit (or
cause to be deposited) into the Escrow Account pursuant to the wire instructions set forth on Schedule A hereto, in immediately available funds, the amount set forth opposite such Investor’s respective name on
Schedule 1 hereto, for a total aggregate amount of US$15,000,000.00, representing the Total Funding Amount referred to in the Funding Agreement (together with all interest and earnings thereon, and less any disbursements
hereunder, the “Escrow Funds”). 
 1.3.    Application of the Escrow Funds. Subject to the
terms, conditions and limitations contained herein and in the Funding Agreement, the Escrow Funds shall be available to be released in accordance with the Funding Agreement and this Escrow Agreement. 

 1.4.    Disbursements of the Escrow Funds. The Escrow Agent shall
only disburse amounts from the Escrow Funds as follows: 
 (a)    Disbursement of the Escrow Funds.

 i.    The Escrow Agent shall disburse amounts then held in the Escrow Account to the applicable party or parties upon
receipt of, and in accordance with, a written notification, in the form of Exhibit B hereto, signed by an authorized representative (a list of whom are provided in Exhibit A-1 to
Exhibit A-15) of each of resTORbio and Investors that funded in the aggregate two-thirds or more of the Total Funding Amount (the
“Requisite Investors”) (a “Joint Written Direction”). resTORbio and each Investor agree solely as between themselves to act in good faith and cause the timely delivery of any applicable Joint Written Direction to
effect the releases or other actions contemplated by the Funding Agreement and this Escrow Agreement in accordance with the timeframes set forth therein and herein. 

ii.    Each of the parties hereto acknowledge and agree that, if one or more of the
Non-Escrow Investors or their Affiliated Entities (as defined in the Funding Agreement), or any other existing investor in Adicet not listed on Schedule 1 (or such investor’s Affiliated Entities),
fund into the Concurrent Private Placement (as defined in the Funding Agreement), a proportionate amount of funds will be released from the Escrow Funds back to the Investors set forth on Schedule 2 in accordance with their pro-rata respective percentages set forth on Schedule 2. Each of resTORbio and the Investors agree to timely execute a Joint Written Direction instructing the Escrow Agent to disburse the Escrow Funds in
accordance with this Section 1.4(a)ii. 
 iii.    Notwithstanding the provisions of Section 1.4(a)i or
Section 1.4(a)ii, in the event that the Escrow Agent receives a copy of a final, non-appealable award or order of a court of competent jurisdiction or arbitrator or arbitration panel forwarded by either
resTORbio or the Requisite Investors, which award or order specifies the specific dollar amounts to be paid out of the Escrow Funds to resTORbio and/or the Investors, and to which such copy resTORbio or the Requisite Investors shall attach payment
instructions (an “Demand Notice”), the Escrow Agent shall distribute (I) to resTORbio, out of the Escrow Funds, any amounts payable to resTORbio as set forth in the order or award and (II) to the Investors, any amounts
payable to the Investors as set forth in the order or award in proportion to the percentages listed on Schedule 1 opposite each such Investor’s respective name; provided that the party delivering the Demand Notice to
the Escrow Agent shall simultaneously provide a copy of such Demand Notice to the other party pursuant to Section 4.4 below (which “other party”, in the case of a Demand Notice from resTORbio, shall be all of the Investors). 

(b)    Any final, non-appealable award or order of a court of competent
jurisdiction or arbitrator or arbitration panel delivered under Section 1.4(a) shall be accompanied by a certificate of or on behalf of the presenting party that such order is final and non-appealable and
from a court of competent jurisdiction or arbitrator or arbitration panel, upon which opinion the Escrow Agent shall be entitled to conclusively rely without further investigation. Any party requesting the disbursement of funds from the Escrow
Account pursuant to a Demand Notice with respect to such an award or order shall include with its delivery of such Demand Notice to the Escrow Agent wire instructions to which the Escrow Agent is instructed to release the funds. 

(c)    Notwithstanding anything to the contrary in this Escrow Agreement, if any amount to be released at any time or
under any circumstances exceeds the balance in the Escrow Account, the Escrow Agent shall release the balance in the Escrow Account and shall have no liability or responsibility to any party for any deficiency. 

  
 2 

 (d)    The Escrow Agent will disburse any amounts from the Escrow Funds
as required by this Section 1.4 within two (2) Business Days (as defined below) or as soon as commercially reasonable thereafter from the date of the Escrow Agent’s receipt of a Joint Written Direction or Demand Notice, as applicable.

 II. Provisions as to the Escrow Agent 

2.1.    Limited Duties of Escrow Agent. The Escrow Agent undertakes to perform only such duties as are expressly set
forth in this Escrow Agreement that shall be deemed purely ministerial in nature. Under no circumstance will the Escrow Agent be deemed to be a fiduciary to any party or any other person under this Escrow Agreement. This Escrow Agreement expressly
and exclusively sets forth the duties of the Escrow Agent with respect to any and all matters pertinent hereto and no implied duties or obligations shall be read into this Escrow Agreement against the Escrow Agent. The Escrow Agent shall not be
bound by, deemed to have knowledge of, or have any obligation to determine, make inquiry into or consider, any term or provision of any agreement between the Investors, resTORbio and/or any other third party or as to which the escrow relationship
created by this Escrow Agreement relates, including without limitation the Funding Agreement or any other documents referenced in this Escrow Agreement. 

2.2. Limitations on Liability of Escrow Agent. 

(a)    In performing its duties under this Escrow Agreement, or upon the claimed failure to perform its duties, the Escrow
Agent shall have no liability except for the Escrow Agent’s fraud, willful misconduct, bad faith or gross negligence. In no event shall the Escrow Agent be liable for incidental, indirect, special, consequential or punitive damages of any kind
whatsoever (including but not limited to lost profits), even if the Escrow Agent has been advised of the likelihood of such loss or damage and regardless of the form of action, other than resulting from the Escrow Agent’s fraud. 

(b)    Except in cases of the Escrow Agent’s fraud, willful misconduct, bad faith or gross negligence, the Escrow
Agent shall be fully protected (i) in acting in reliance upon any certificate, statement, request, notice, advice, instruction, direction, other agreement or instrument or signature reasonably and in good faith provided by any Investor or
resTORbio with respect to such party’s information and believed by the Escrow Agent to be genuine, (ii) in assuming that any person purporting to give the Escrow Agent any of the foregoing in connection with either this Escrow Agreement or
the Escrow Agent’s duties has been duly authorized to do so and (iii) in acting or failing to act in good faith in accordance with the terms of this Escrow Agreement on the advice of outside counsel retained by the Escrow Agent. 

(c)    The Escrow Agent shall have no liability with respect to the transfer or distribution of any funds effected by the
Escrow Agent pursuant to wiring or transfer instructions provided to the Escrow Agent in accordance with the provisions of this Escrow Agreement. The Escrow Agent shall be entitled to rely upon all bank and account information provided to the Escrow
Agent by the applicable authorized representative of each of resTORbio and an Investor set forth on Exhibit A-1 to Exhibit A-15. The Escrow Agent shall
have no duty to verify or otherwise confirm any written wire transfer instructions except as set forth in Section 2.3 below, but it may do so in its discretion on any occasion without incurring any liability to any party for failing to do so on
any other occasion. The Escrow Agent shall process all wire transfers based on bank identification and account numbers rather than the names of the intended recipient of the funds, even if such numbers pertain to a recipient other than the recipient
identified in the payment instructions. The Escrow Agent shall have no duty to detect any such inconsistencies and shall resolve any such inconsistencies by using the account number. In connection with any payments that the Escrow Agent is
instructed to make by wire transfer, the Escrow Agent shall not be liable for the acts or omissions of (i) any Investor, resTORbio or other person providing such instructions, including without limitation errors

  
 3 

 
as to the amount, bank information or bank account number; or (ii) any other person or entity, including without limitation any Federal Reserve Bank, any transmission or communications
facility, any funds transfer system, any receiver or receiving depository financial institution, and no such person or entity shall be deemed to be an agent of the Escrow Agent. Any wire transfers of funds made by the Escrow Agent pursuant to this
Escrow Agreement will be made subject to and in accordance with the Escrow Agent’s usual and ordinary wire transfer procedures in effect from time to
time.                 
 (d)    No
provision of this Escrow Agreement shall require the Escrow Agent to risk or advance its own funds or otherwise incur any financial liability or potential financial liability in the performance of its duties or the exercise of its rights under this
Escrow Agreement. The Escrow Agent shall not be obligated to take any legal action or to commence any proceedings in connection with this Escrow Agreement or any property held hereunder or to appear in, prosecute or defend in any such legal action
or proceedings. 
 2.3.    Security Procedure For Funds Transfers. The Escrow Agent shall confirm each funds
transfer instruction received in the name of a party by telephone call-back to an Authorized Representative specified on Exhibit A-1 to Exhibit A-15 at the
telephone number specified for such authorized person on Exhibit A-1 to Exhibit A-15, as applicable (“Authorized Representative”). Once
delivered to the Escrow Agent, Exhibit A-1 to Exhibit A-15 may be revised or rescinded only by a writing signed by an Authorized Representative of the
applicable party. Such revisions or rescissions shall be effective only after actual receipt and following such period of time as may be necessary to afford the Escrow Agent a reasonable opportunity to act on it. If a revised Exhibit A-1 to Exhibit A-15 or a rescission of an existing Exhibit A-1 to Exhibit A-15 is delivered to the Escrow Agent by an entity that is a successor-in-interest to such party, such document shall be
accompanied by additional documentation satisfactory to the Escrow Agent showing that such entity has succeeded to the rights and responsibilities of the applicable authorized representative of each of resTORbio and any Investor under this Escrow
Agreement. resTORbio and each Investor understand that the Escrow Agent’s inability to receive or confirm funds transfer instructions pursuant to the above security procedure may result in a delay in accomplishing such funds transfer, and agree
that the Escrow Agent shall not be liable for any loss caused by any such delay. 
 2.4.    Depository Role. The
Escrow Agent acts hereunder as a depository only, and is not responsible or liable in any manner whatsoever for the sufficiency, correctness, genuineness or validity of the subject matter of this Escrow Agreement or any part thereof, or of any
person executing or depositing such subject matter. 
 2.5.    No Duty to Notify. The Escrow Agent shall in no
way be responsible for nor shall it be its duty to notify any party hereto or any other party interested in this Escrow Agreement of any payment required or maturity occurring under this Escrow Agreement or under the terms of any instrument
deposited therewith unless such notice is explicitly provided for in this Escrow Agreement. 
 2.6.    Other
Relationships. The Escrow Agent may execute any of its powers and perform any of its duties hereunder directly or through affiliates or agents. The Escrow Agent and its affiliates, and any of their respective directors, officers or employees may
become pecuniarily interested in any transaction in which any of the other parties hereto may be interested and may contract and lend money to any such party and otherwise act as fully and freely as though it were not escrow agent under this Escrow
Agreement. Nothing herein shall preclude the Escrow Agent or its affiliates from acting in any other capacity for any such party. 

2.7.    Disputes. 

(a)    In the event of any disagreement between resTORbio and any Investor, or between either of them and any other party,
resulting in adverse claims or demands being made in connection with the 

  
 4 

 
matters covered by this Escrow Agreement, or in the event that the Escrow Agent, in good faith, be in doubt as to what action it should take hereunder, the Escrow Agent may, at its option, refuse
to comply with any claims or demands on it, or refuse to take any other action hereunder, so long as such disagreement continues or such doubt exists, and in any such event, the Escrow Agent shall not be or become liable in any way or to any party
for its failure or refusal to act, and the Escrow Agent shall be entitled to continue to refrain from acting until directed by (i) an order of a court of competent jurisdiction, or (ii) directed otherwise a Joint Written Direction.
Notwithstanding the preceding, the Escrow Agent may in its discretion obey the order, judgment, decree or levy of any court, whether with or without jurisdiction, or of an agency of the United States or any political subdivision thereof, or of any
agency of any State of the United States or of any political subdivision thereof, and the Escrow Agent is hereby authorized in its sole discretion, to comply with and obey any such orders, judgments, decrees or levies. The Escrow Agent shall be
under no duty to institute or defend any legal proceedings, although the Escrow Agent may, in its discretion and at the expense of resTORbio and the Investors as provided in the immediately following paragraph, institute or defend such proceedings.
The rights of the Escrow Agent under this sub-paragraph are cumulative of all other rights which it may have by law or otherwise. 

(b)    In the event of any disagreement or doubt, as described above, the Escrow Agent shall have the right, in addition
to the rights described above and at the election of the Escrow Agent, to tender into the registry or custody of any court having jurisdiction, all funds, equity and property held under this Escrow Agreement, and the Escrow Agent shall have the
right to take such other legal action as may be appropriate or necessary, in the sole discretion of the Escrow Agent. Upon acceptance of any such tender and transfer of all funds, equity and property held under this Escrow Agreement, resTORbio and
the Investors agree that the Escrow Agent shall be discharged from all further duties under this Escrow Agreement. 

2.8.    Indemnification. resTORbio and each Investor jointly and severally agree to defend, indemnify and hold
harmless the Escrow Agent and each of the Escrow Agent’s officers, directors, agents and employees (the “Escrow Indemnified Parties”) from and against any and all losses, liabilities, claims, damages, expenses and costs
(including, without limitation, attorneys’ fees and expenses) of every nature whatsoever (collectively, “Escrow Agent Losses”) which any such Escrow Indemnified Party may incur and which arise directly or indirectly from this
Escrow Agreement or which arise directly or indirectly by virtue of the Escrow Agent’s undertaking to serve as the Escrow Agent hereunder; provided, however, that no Escrow Indemnified Party shall be entitled to indemnity with
respect to Escrow Agent Losses that have been finally adjudicated by a court of competent jurisdiction to have been caused by such Escrow Indemnified Party’s fraud, gross negligence, bad faith or willful misconduct. resTORbio and each Investor
agree solely between themselves, and without affecting any Escrow Indemnified Party’s right to indemnification hereunder, that (i) resTORbio and the Investors shall each be responsible for fifty percent (50%) of such indemnification
obligations and shall have a right of contribution against the other to the extent that they pay more than their fifty percent (50%) share of such indemnification obligations and (ii) each Investor shall be responsible for the percentage of
such indemnification obligations borne by the Investors set forth opposite such Investor’s respective name on Schedule 1 hereto and shall have a right of contribution against the other to the extent that such Investor
pays more than its respective share of such indemnification obligations. The provisions of this section shall survive the termination of this Escrow Agreement and any resignation or removal of the Escrow Agent. 

2.9.    Mergers, Consolidations, Etc. Any entity into which the Escrow Agent may be merged or converted or with
which it may be consolidated, or any entity to which all or substantially all the escrow business of the Escrow Agent may be transferred, shall be the successor Escrow Agent under this Escrow Agreement and shall have and succeed to the rights,
powers, duties, immunities and privileges as its predecessor, in each case without the execution or filing of any instrument or paper or the performance of any further act (other than due notice to resTORbio and each Investor). 

  
 5 

 2.10.    Resignation; Removal. 

(a)    The Escrow Agent may resign and be discharged from it duties and obligations at any time under this Escrow
Agreement by providing written notice to resTORbio and each Investor and complying with the provisions of this Section 2.10(a). Such resignation shall be effective on later of the date set forth in such written notice, which shall be no earlier
than thirty (30) days after such written notice has been furnished, and the date that a successor agent has been appointed or final sentence of this Section 2.10(a) has been complied with. Thereafter, the Escrow Agent shall have no further
obligation except to hold the Escrow Funds as depository and cooperate reasonably in the transfer of the Escrow Funds to a successor escrow agent. resTORbio and the Requisite Investors shall promptly appoint a successor escrow agent. The Escrow
Agent shall refrain from taking any action until it shall receive a Joint Written Direction designating the successor escrow agent. However, in the event no successor escrow agent has been appointed on or prior to the date such resignation is to
become effective, the Escrow Agent shall be entitled to tender into the custody of any court of competent jurisdiction all funds, equity and other property then held by the Escrow Agent hereunder and the Escrow Agent shall, upon acceptance of any
such tender and transfer of all funds, equity and property held under this Escrow Agreement, be relieved of all further duties and obligations under this Escrow Agreement. 

(b)    resTORbio and the Requisite Investors acting together shall have the right to terminate the appointment of the
Escrow Agent upon thirty (30) days’ joint written notice to the Escrow Agent specifying the date upon which such termination shall take effect. Thereafter, the Escrow Agent shall have no further obligation except to hold the Escrow Funds
as depository and cooperate reasonably in the transfer of the Escrow Funds to a successor escrow agent. The Escrow Agent shall refrain from taking any action until it shall receive a Joint Written Direction designating the successor escrow agent.
However, in the event no successor escrow agent has been appointed on or prior to the date such termination is to become effective, the Escrow Agent shall be entitled to tender into the custody of any court of competent jurisdiction all funds,
equity and other property then held by the Escrow Agent hereunder and the Escrow Agent shall, upon acceptance of any such tender and transfer of all funds, equity and property held under this Escrow Agreement, be relieved of all further duties and
obligations under this Escrow Agreement. 
 (c)    In the case of a resignation or removal of the Escrow Agent, the
Escrow Agent shall have no responsibility for the appointment of a successor escrow agent hereunder. The successor escrow agent appointed by resTORbio and the Requisite Investors shall execute, acknowledge and deliver to the Escrow Agent and the
other parties an instrument in writing accepting its appointment hereunder, and thereafter, the Escrow Agent shall deliver all of the then-remaining balance of the Escrow Funds, less any fees and expenses then incurred by and unpaid to the Escrow
Agent, to such successor escrow agent in accordance with the Joint Written Direction of resTORbio and the Requisite Investors and upon receipt of the Escrow Funds, the successor escrow agent shall be bound by all of the provisions of this Escrow
Agreement. 
 2.11.    Compensation of the Escrow Agent. [Reserved.] 

III. Tax Matters 
 3.1. Tax
Matters. 
 (a)    On or before the execution and delivery of this Escrow Agreement, each of resTORbio and each
Investor shall provide to the Escrow Agent a completed IRS Form W-9 or Form W-8 (or, in each case, any successor form), as applicable, and shall promptly update any such
form to the extent such form becomes obsolete or inaccurate in any respect. The Escrow Agent shall have the right to request from any party to this Escrow Agreement, or any other person or entity entitled to payment hereunder, any additional forms,
documentation or other information as may be reasonably necessary for the Escrow Agent to satisfy its reporting and withholding obligations under the Internal Revenue Code of 1986, as amended (the 

  
 6 

 
“Code”) and applicable state and local income tax law. To the extent any such forms to be delivered under this Section 3.1(a) are not provided prior to the date hereof or by
the time the related payment is required to be made or are determined by the Escrow Agent to be incomplete and/or inaccurate in any respect, the Escrow Agent shall be entitled to withhold (without liability) a portion of any interest or other income
earned on the investment of the Escrow Funds or on any such payments hereunder to the extent withholding is required by law and shall remit such taxes to the appropriate authorities, and shall have no obligation to gross up any such payment. The
Escrow Agent shall have the sole right to make the determination as to which payments hereunder are “reportable payments” or “withholdable payments” under the Code. 

(b)    resTORbio and each Investor agree that, subject to the terms and conditions of this Escrow Agreement, the owners of
the funds held in the Escrow Account (together with any interest or other income earned on the investment of the Escrow Funds) are the Investors (pro rata in proportion to the percentages listed on Schedule 1 opposite each such Investor’s
respective name) for all tax purposes and the Escrow Agent shall report to the Internal Revenue Service (“IRS”), as of each calendar year-end, all income earned from the investment of any sum
held in the Escrow Account (including income earned in respect of such earnings) as the income of the Investors for purposes of the Code and applicable state and local income tax law. The Escrow Agent is authorized and directed to report all
interest and other income earned on the Escrow Funds in accordance with the IRS Form W-9 or Form W-8 provided to the Escrow Agent by the Investors. Each Investor shall
report all interest or other income, if any, that is earned on the Escrow Funds as income in the taxable year or years in which such income is properly includable in such Investor’s gross income and shall pay any and all taxes attributable
thereto. 
 (c)    Notwithstanding anything to the contrary herein provided, except for the delivery of IRS Form 1099,
IRS Form 1042-S or other applicable tax form, the Escrow Agent shall have no duty to prepare or file any Federal or state tax report or return with respect to any funds or equity held pursuant to this Escrow
Agreement or any income earned thereon other than such information reports as the Escrow Agent is required to prepare and file as required by applicable law. The Escrow Agent shall have no responsibility to report any payments from the Escrow Fund
other than the interest or other income earned on the Escrow Fund as set forth in this Section 3.1. 

(d)    resTORbio and each Investor jointly and severally, shall indemnify, defend and hold the Escrow Agent harmless from
and against any tax, late payment, interest, penalty or other cost or expense that may be assessed against the Escrow Agent on or with respect to the funds and equity held under this Escrow Agreement or any earnings or interest thereon, unless such
tax, late payment, interest, penalty or other cost or expense was finally adjudicated by a court of competent jurisdiction to have been directly caused by the fraud, gross negligence, bad faith or willful misconduct of the Escrow Agent or the
failure of the Escrow Agent to follow the lawful instructions of resTORbio or any Investor. The indemnification provided in this section is in addition to the indemnification provided to the Escrow Agent elsewhere in this Escrow Agreement. resTORbio
and each Investor agree solely between themselves, and without affecting the Escrow Agent’s right to indemnification hereunder, that (i) resTORbio and the Investors shall each be responsible for fifty percent (50%) of such indemnification
obligations and shall have a right of contribution against the other to the extent that they pay more than their fifty percent (50%) share of such indemnification obligations and (ii) each Investor shall be responsible for the percentage of
such indemnification obligations borne by the Investors set forth opposite such Investor’s respective name on Schedule 1 hereto and shall have a right of contribution against the other to the extent that such Investor
pays more than its respective share of such indemnification obligations. The indemnification provided in this section is in addition to the indemnification provided in Section 2.8 and shall survive the resignation or removal of the Escrow Agent
and the termination of this Escrow Agreement. 

  
 7 

 IV. Miscellaneous 

4.1.    Disbursements. The Escrow Agent shall make no disbursement, investment or other use of funds until and
unless it has collected funds. The Escrow Agent shall not be liable for collection items until such proceeds have been received or the Federal Reserve has given the Escrow Agent credit for the funds. 

4.2.    Permitted Investments. The Escrow Agent shall invest the Escrow Funds in a PNC Non-Interest Bearing Deposit Account, unless Schedule C is completed to provide direction for investment in the Money Market Deposit Account. Information relating to investment of Escrow Funds in a PNC Non-Interest Bearing Deposit Account or, if elected, the Money Market Deposit Account, are set forth on Schedule C. resTORbio and each Investor recognize and agree that the Escrow Agent will not provide
supervision, recommendations or advice relating to the investment of moneys held hereunder or the purchase, sale, retention or other disposition of any investment, and the Escrow Agent shall not be liable to resTORbio or any Investor or any other
person or entity for any loss incurred in connection with any such investment, including, without limitation, any loss due to interest rate fluctuation, early withdrawal penalty or the decline in value of any investment. Any investment earnings and
income on the funds held in the Escrow Account shall become part of the Escrow Account and shall be disbursed in accordance with this Escrow Agreement. The Escrow Agent shall not be liable or responsible for any loss resulting from any deposits or
investments made pursuant to this Section 4.2, other than as a result of the fraud, gross negligence, bad faith or willful misconduct of the Escrow Agent. 

4.3.    Accounting. The Escrow Agent shall provide monthly reports of transactions and holdings to resTORbio and
each Investor as of the end of each month, at the address provided by resTORbio and each Investor. 

4.4.    Notices. Any notice, request for consent, report, or any other communication required or permitted in this
Escrow Agreement shall be in writing and shall be deemed to have been given when delivered by electronic mail to the e-mail address given below, provided that written confirmation of receipt is obtained
promptly from the recipient after completion of the electronic mail transmission. 
 If to the Escrow Agent:     

PNC Bank, National Association 

Attn: Heather Kelly; Rachel Stastny 

80 South 8th Street, Suite 3715 

Minneapolis, Minnesota 55402 

Email: hkelly @pnc.com; Rachel.stastny@pnc.com 

            pncpaidadmin@pnc.com 

Phone: 612-268-7307 

If to resTORbio:     

resTORbio, Inc. 
 500 Boylston
Street, 13th Floor 
 Boston, Massachusetts 

Attention: Chen Schor 
 Email:
cschor@restorbio.com 

  
 8 

 with a copy (which shall not constitute notice) to each of: 

Morrison & Foerster LLP 

12531 High Bluff Drive, Suite 100 

San Diego, CA 92011 
 Attention:
James M. Krenn 
 Email: jkrenn@mofo.com 

Goodwin Procter LLP 
 100 Northern
Avenue 
 Boston, Massachusetts 02210 

Attention: Andrew H. Goodman 

Email: agoodman@goodwinlaw.com 

If to any Investor: To the email and address set forth on such Investor’s signature page hereto. 

Any party may unilaterally designate a different address by giving notice of each change in the manner specified above to each other party. In
all cases, the Escrow Agent shall be entitled to rely on a copy or electronic transmission of any document with the same legal effect as if it were the original of such document. “Business Day” shall mean any day other than a
Saturday, Sunday or any other day on which banking institutions located in Pennsylvania are authorized or obligated by law or executive order to close. The parties acknowledges that there are certain security, corruption, transmission error and
access availability risks associated with using open networks such as the internet and Parties assumes such risks and acknowledges that the security procedures set forth herein are commercially reasonable. 

4.5.    Governing Law. This Escrow Agreement shall be governed by and construed according to the laws of the State
of Delaware, without regard to principles of conflicts of law. The parties hereto consent to the exclusive jurisdiction of the state and federal courts sitting in the state of Delaware and consent to personal jurisdiction of and venue in such courts
with respect to any and all matters or disputes arising out of this Escrow Agreement. 
 4.6.    Waiver of Jury
Trial. TO THE EXTENT NOT PROHIBITED BY APPLICABLE LAW THAT CANNOT BE WAIVED, EACH PARTY HEREBY WAIVES, AND COVENANTS THAT IT WILL NOT ASSERT (WHETHER AS PLAINTIFF, DEFENDANT OR OTHERWISE), ANY RIGHT TO TRIAL BY JURY IN ANY FORUM IN RESPECT OF
ANY ISSUE, CLAIM, DEMAND, ACTION OR CAUSE OF ACTION ARISING IN WHOLE OR IN PART UNDER, RELATED TO, BASED ON OR IN CONNECTION WITH THIS ESCROW AGREEMENT OR THE SUBJECT MATTER HEREOF, WHETHER NOW EXISTING OR HEREAFTER ARISING AND WHETHER SOUNDING IN
TORT OR CONTRACT OR OTHERWISE. ANY PARTY HERETO MAY FILE AN ORIGINAL COUNTERPART OR A COPY OF THIS SECTION 4.6 WITH ANY COURT AS WRITTEN EVIDENCE OF THE CONSENT OF EACH SUCH PARTY TO THE WAIVER OF ITS RIGHT TO TRIAL BY JURY. 

4.7.    Assignment; Binding Effect. Except as permitted in Section 2.9, neither this Escrow Agreement nor any
rights or obligations hereunder may be assigned by any party hereto without the express written consent of each of the other parties hereto. This Escrow Agreement shall inure to and be binding upon the parties hereto and their respective successors,
heirs and permitted assigns. 
 4.8.    Amendment and Waiver. The terms of this Escrow Agreement may be altered,
amended, modified or revoked only by an instrument in writing signed by the Escrow Agent, resTORbio and the Requisite Investors. No course of conduct shall constitute a waiver of any terms or conditions of this

  
 9 

 
Escrow Agreement, unless such waiver is specified in writing, and then only to the extent so specified. A waiver of any of the terms and conditions of this Escrow Agreement on one occasion shall
not constitute a waiver of the other terms of this Escrow Agreement, or of such terms and conditions on any other occasion. 

4.9.    Severability. If any provision of this Escrow Agreement shall be held or deemed to be or shall in fact, be
illegal, inoperative or unenforceable, the same shall not affect any other provision or provisions herein contained or render the same invalid, inoperative or unenforceable to any extent whatsoever. 

4.10.    Further Assurances. If at any time the Escrow Agent shall determine or be advised that any further
agreements, assurances or other documents are reasonably necessary or desirable to carry out the provisions of this Escrow Agreement and the transactions contemplated by this Escrow Agreement, the parties shall execute and deliver any and all such
agreements or other documents and do all things reasonably necessary or appropriate to carry out fully the provisions of this Escrow Agreement. 

4.11.    No Third Party Beneficiaries. This Escrow Agreement is for the sole benefit of the parties hereto, and
their respective successors and permitted assigns, and nothing herein, express or implied, is intended to or shall confer upon any other person or entity any legal or equitable right, benefit or remedy of any nature whatsoever under or by reason of
this Escrow Agreement. Additionally, any permitted assignee must also satisfy the Escrow Agent’s requirements set forth in Section 2.9. 

4.12.    Force Majeure. No party to this Escrow Agreement shall be liable to any other party hereto for losses due
to, or if it is unable to perform its obligations under the terms of this Escrow Agreement because of, acts of God, fire, war, terrorism, floods, strikes, electrical outages, equipment or transmission failure, interruption or malfunctions of
communications or power supplies, labor difficulties, actions of public authorities or other similar causes reasonably beyond its control. 

4.13.    Termination. This Escrow Agreement shall terminate upon the distribution by the Escrow Agent in accordance
with this Escrow Agreement of all funds, equity and property held under this Escrow Agreement or upon the earlier Joint Written Direction. 

4.14.    Titles and Headings. All titles and headings in this Escrow Agreement are intended solely for convenience
of reference and shall in no way limit or otherwise affect the interpretation of any of the provisions hereof. 

4.15.    Counterparts; Facsimile Execution. This Escrow Agreement may be executed in one or more counterparts, each
of which shall be deemed an original but all of which together shall constitute one and the same instrument. Delivery of an executed signature page to this Escrow Agreement and agreements, certificates, instruments and documents entered into in
connection herewith by facsimile or other electronic transmission (including Adobe PDF format) will be effective as delivery of a manually executed counterpart to this Escrow Agreement or such agreements, certificates, instruments and documents.

 4.16.    Entire Agreement; Effect of Definitive. This Escrow Agreement constitutes the entire agreement
between the Escrow Agent and resTORbio and the Investors in connection with the subject matter of this Escrow Agreement, and no other agreement entered into between resTORbio and any Investor, or either of them, including, without limitation, and
the Funding Agreement, shall be considered as adopted or binding, in whole or in part, upon the Escrow Agent notwithstanding that any such other agreement may be deposited with the Escrow Agent or the Escrow Agent may have knowledge thereof. The
parties hereto acknowledge and agree that the Escrow Agent is not a party to, is not bound by, and has no duties or obligations under the Funding Agreement, that all references in this Escrow Agreement to the Funding Agreement are for convenience,
and that the Escrow Agent shall have no implied duties beyond the express duties set forth in this Escrow Agreement. 

  
 10 

 4.17.    Procedures for Opening a New Account. IMPORTANT
INFORMATION ABOUT PROCEDURES FOR OPENING A NEW ACCOUNT: To help the government fight the funding of terrorism and money laundering activities, Federal law requires all financial institutions to obtain, verify and record information that identifies
each person who opens an account. When a party opens an account, the Escrow Agent must obtain each party’s name, address, date of birth (as applicable), taxpayer or other government identification number or other appropriate information that
will allow the Escrow Agent to identify such party. The Escrow Agent may also ask to see each party’s driver’s license, passport or other identifying documents. For parties that are business or other legal entities, the Escrow Agent may
require such documents as it deems necessary to confirm the legal existence of the entity. 
 [Signature Page Follows] 

  
 11 

 IN WITNESS WHEREOF, the parties hereto have caused this Escrow Agreement to be executed as
of the date first above written. 
  

			
	PNC BANK, NATIONAL ASSOCIATION, as the
	Escrow Agent

 
			
		
	By:	 	 /s/ Rachel Stastny

			
	Name:	 	 Rachel Stastny

 
			
	Title:	 	 Vice President

  
 12 

 
			
	RESTORBIO, INC.

 
			
		
	By:	 	 /s/ Chen Schor

 

			
	Name:	 	 Chen Schor

 
			
	Title:	 	 Chief Executive Officer

  
 13 

 
			
	INVESTOR:
		
	By:	 	
		
	By:	 	
		
	By:	 	  

	Name:	 	  

	Title:	 	  

		
	Address:	 	
		 	
	Email:	 	

  
 14

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00314-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00314-of-00352.parquet"}]]